Blood and lymphatic system disorders – page 60

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

Study on the Effectiveness and Safety of Mitapivat for Children with Pyruvate Kinase Deficiency Receiving Regular Blood Transfusions

Study on the Effectiveness and Safety of Mitapivat for Children with Pyruvate Kinase Deficiency Receiving Regular Blood Transfusions

Study of BI-1206, Rituximab, and Acalabrutinib for Patients with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma

Study on Voxelotor for Reducing Hemolysis in Patients with Sickle Cell Disease

Study on Voxelotor for Reducing Hemolysis in Patients with Sickle Cell Disease

Study on CLIC-1901 CAR T-cells and Tocilizumab for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin Lymphoma

Study on CLIC-1901 CAR T-cells and Tocilizumab for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin Lymphoma

Study of CYC140 oral medication for patients with advanced solid tumors and lymphoma

Study of CYC140 oral medication for patients with advanced solid tumors and lymphoma

Study on the Effectiveness and Safety of Mitapivat for Patients with Sickle Cell Disease

Study on the Effectiveness and Safety of Mitapivat for Patients with Sickle Cell Disease

Study of venetoclax and azacitidine combination treatment for acute myeloid leukemia patients with measurable residual disease after chemotherapy or before stem cell transplant

Study of venetoclax and azacitidine combination treatment for acute myeloid leukemia patients with measurable residual disease after chemotherapy or before stem cell transplant

Study of Talquetamab and Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma

Study of Talquetamab and Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma

Study on Continuing Elotuzumab Treatment for Patients with Multiple Myeloma from Previous Trials

Study on Continuing Elotuzumab Treatment for Patients with Multiple Myeloma from Previous Trials

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

Study of luspatercept in patients with low-risk myelodysplastic syndrome (MDS) who do not require blood transfusions and have not received erythropoiesis treatment

Study of luspatercept in patients with low-risk myelodysplastic syndrome (MDS) who do not require blood transfusions and have not received erythropoiesis treatment